H02 Stock Overview
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||S$11.94|
|52 Week High||S$13.80|
|52 Week Low||S$10.96|
|1 Month Change||5.38%|
|3 Month Change||-2.53%|
|1 Year Change||6.42%|
|3 Year Change||-1.16%|
|5 Year Change||26.22%|
|Change since IPO||462.16%|
Recent News & Updates
Haw Par (SGX:H02) Will Pay A Dividend Of S$0.15
The board of Haw Par Corporation Limited ( SGX:H02 ) has announced that it will pay a dividend of S$0.15 per share on...
|H02||SG Pharmaceuticals||SG Market|
Return vs Industry: H02 underperformed the SG Pharmaceuticals industry which returned 17% over the past year.
Return vs Market: H02 exceeded the SG Market which returned 4.4% over the past year.
|H02 Average Weekly Movement||2.8%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||4.7%|
|10% most volatile stocks in SG Market||13.5%|
|10% least volatile stocks in SG Market||2.1%|
Stable Share Price: H02 is not significantly more volatile than the rest of SG stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: H02's weekly volatility (3%) has been stable over the past year.
About the Company
|1969||n/a||Ee Lim Wee||https://www.hawpar.com|
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company operates through three segments: Healthcare, Investments, and Others. The Healthcare segment principally manufactures and distributes topical analgesic products.
Haw Par Fundamentals Summary
|H02 fundamental statistics|
Is H02 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|H02 income statement (TTM)|
|Cost of Revenue||S$56.29m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.37|
|Net Profit Margin||85.18%|
How did H02 perform over the long term?See historical performance and comparison
2.5%Current Dividend Yield
Is Haw Par undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: H02 (SGD11.94) is trading above our estimate of fair value (SGD8.56)
Significantly Below Fair Value: H02 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: H02 is poor value based on its PE Ratio (32.3x) compared to the Asian Pharmaceuticals industry average (26x).
PE vs Market: H02 is poor value based on its PE Ratio (32.3x) compared to the SG market (13.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate H02's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: H02's PB Ratio (0.8x) is in line with the SG Pharmaceuticals industry average.
How is Haw Par forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Haw Par has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Haw Par performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: H02 has high quality earnings.
Growing Profit Margin: H02's current net profit margins (85.2%) are lower than last year (88.6%).
Past Earnings Growth Analysis
Earnings Trend: H02's earnings have grown by 1.5% per year over the past 5 years.
Accelerating Growth: H02's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: H02 had negative earnings growth (-49.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.3%).
Return on Equity
High ROE: H02's Return on Equity (2.6%) is considered low.
How is Haw Par's financial position?
Financial Position Analysis
Short Term Liabilities: H02's short term assets (SGD612.3M) exceed its short term liabilities (SGD63.7M).
Long Term Liabilities: H02's short term assets (SGD612.3M) exceed its long term liabilities (SGD956.0K).
Debt to Equity History and Analysis
Debt Level: H02 is debt free.
Reducing Debt: H02 has no debt compared to 5 years ago when its debt to equity ratio was 2.1%.
Debt Coverage: H02 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: H02 has no debt, therefore coverage of interest payments is not a concern.
What is Haw Par current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: H02's dividend (2.51%) is higher than the bottom 25% of dividend payers in the SG market (2%).
High Dividend: H02's dividend (2.51%) is low compared to the top 25% of dividend payers in the SG market (5.49%).
Stability and Growth of Payments
Stable Dividend: H02's dividend payments have been volatile in the past 10 years.
Growing Dividend: H02's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (81.2%), H02's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ee Lim Wee (60 yo)
Mr. Ee Lim Wee serves as Deputy Chairman at UOL Group Limited. Mr. Wee has been the Chief Executive Officer and President of Haw Par Corporation Limited since October 27, 2003. Mr. Wee has been an Acting P...
CEO Compensation Analysis
Compensation vs Market: Ee Lim's total compensation ($USD1.36M) is about average for companies of similar size in the SG market ($USD1.11M).
Compensation vs Earnings: Ee Lim's compensation has been consistent with company performance over the past year.
Experienced Management: H02's management team is seasoned and experienced (10.5 years average tenure).
Experienced Board: H02's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Haw Par Corporation Limited's employee growth, exchange listings and data sources
- Name: Haw Par Corporation Limited
- Ticker: H02
- Exchange: SGX
- Founded: 1969
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: S$2.642b
- Shares outstanding: 221.29m
- Website: https://www.hawpar.com
Number of Employees
- Haw Par Corporation Limited
- No. 03-03 Haw Par Technocentre
- 401 Commonwealth Drive
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/17 16:15|
|End of Day Share Price||2022/01/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.